KNSA - Kiniksa Pharmaceuticals Ltd Stock Price, Fair Value and News

16.97USD+0.06 (+0.35%)Delayed as of 22 Apr 2024, 11:55 am ET

Market Summary

USD16.97+0.06

Delayedas of 22 Apr 2024, 11:55 am

0.35%

KNSA Stock Price

View Fullscreen

KNSA RSI Chart

KNSA Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

84.12

Price/Sales (Trailing)

4.38

EV/EBITDA

-75.24

Price/Free Cashflow

89.95

KNSA Price/Sales (Trailing)

KNSA Profitability

EBT Margin

-6.16%

Return on Equity

3.21%

Return on Assets

2.68%

Free Cashflow Yield

1.11%

KNSA Fundamentals

KNSA Revenue

Revenue (TTM)

270.3M

Rev. Growth (Yr)

34.76%

Rev. Growth (Qtr)

24.38%

KNSA Earnings

Earnings (TTM)

14.1M

Earnings Growth (Yr)

465.73%

Earnings Growth (Qtr)

282.15%

Breaking Down KNSA Revenue

52 Week Range

10.6520.65

(Low)(High)

Last 7 days

-2.0%

Last 30 days

-14.4%

Last 90 days

-10.3%

Trailing 12 Months

47.9%

How does KNSA drawdown profile look like?

KNSA Financial Health

Current Ratio

4.34

KNSA Investor Care

Shares Dilution (1Y)

0.98%

Diluted EPS (TTM)

0.2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	236.3M	280.8M	248.7M	270.3M
2022	84.0M	129.4M	174.8M	220.2M
2021	0	0	0	38.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Kiniksa Pharmaceuticals Ltd

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 08, 2024	paolini john f.	sold (taxes)	-13,120	17.9	-733	chief medical officer
Apr 08, 2024	patel sanj k	sold (taxes)	-72,942	17.9	-4,075	chairman & ceo
Apr 08, 2024	moat ross	acquired	-	-	2,477	chief commercial officer
Apr 08, 2024	megna michael r	acquired	-	-	3,932	chief accounting officer
Apr 08, 2024	paolini john f.	acquired	-	-	2,497	chief medical officer
Apr 08, 2024	tessari eben	sold (taxes)	-14,337	17.9	-801	chief operating officer
Apr 08, 2024	megna michael r	sold (taxes)	-29,821	17.9	-1,666	chief accounting officer
Apr 08, 2024	tessari eben	acquired	-	-	2,726	chief operating officer
Apr 08, 2024	ragosa mark	sold (taxes)	-14,158	17.9	-791	chief financial officer
Apr 08, 2024	ragosa mark	acquired	-	-	2,694	chief financial officer

Which funds bought or sold KNSA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	18.39	300,277	1,205,620	-%
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	added	29.22	768,760	2,463,840	0.13%
Apr 15, 2024	Legato Capital Management LLC	unchanged	-	146,550	1,320,290	0.16%
Apr 11, 2024	Fortitude Family Office, LLC	unchanged	-	546	4,913	-%
Apr 09, 2024	ADIRONDACK TRUST CO	unchanged	-	-1,233	17,255	0.01%
Apr 05, 2024	GAMMA Investing LLC	added	9.35	3,080	16,849	-%
Apr 05, 2024	CWM, LLC	added	10.24	1,000	3,000	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	reduced	-4.98	177,669	2,759,240	0.01%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	new	-	5,262	5,262	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	105	105	-%

Are Funds Buying or Selling KNSA?

Are funds buying KNSA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KNSA

No. of Funds

Unveiling Kiniksa Pharmaceuticals Ltd's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	blackrock inc.	10.5%	4,192,446	SC 13G/A
Feb 14, 2024	fairmount funds management llc	8.1%	2,883,221	SC 13G/A
Feb 14, 2024	hhlr advisors, ltd.	9.9%	3,879,426	SC 13G/A
Feb 13, 2024	vanguard group inc	8.37%	2,965,299	SC 13G/A
Feb 12, 2024	rubric capital management lp	8.21%	2,907,501	SC 13G
Jan 25, 2024	blackrock inc.	9.0%	3,180,588	SC 13G
Aug 18, 2023	hhlr advisors, ltd.	9.9%	3,541,301	SC 13G/A
Aug 10, 2023	fairmount funds management llc	6.1%	2,143,052	SC 13G
Mar 08, 2023	blackrock inc.	4.9%	3,427,741	SC 13G/A
Feb 14, 2023	hhlr advisors, ltd.	7.6%	2,623,924	SC 13G/A

Recent SEC filings of Kiniksa Pharmaceuticals Ltd

View All Filings

Date Filed	Form Type	Document
Apr 10, 2024	PRE 14A	PRE 14A
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 05, 2024	SC 13G/A	Major Ownership Report
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading

Peers (Alternatives to Kiniksa Pharmaceuticals Ltd)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Kiniksa Pharmaceuticals Ltd News

Latest updates

Kiniksa Pharmaceuticals Ltd Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2
Revenue	24.4%	83,395,000	67,046,000	71,473,000	48,345,000	61,884,000	99,135,000	26,972,000	32,189,000	22,142,000	12,095,000	7,704,000
S&GA Expenses	6.6%	36,739,000	34,468,000	29,175,000	29,045,000	27,215,000	24,677,000	23,841,000	22,218,000	22,741,000	20,759,000	21,848,000
R&D Expenses	17.2%	20,052,000	17,106,000	23,767,000	15,172,000	14,390,000	16,485,000	13,798,000	20,817,000	27,433,000	19,236,000	23,945,000
EBITDA Margin	-33.6%	-0.05	-0.04	0.16	0.12	0.06	-0.17	-0.82	-1.52	-4.00	-	-
Income Taxes	-525.4%	-22,787,000	5,356,000	-16,211,000	2,906,000	2,380,000	-177,358,000	716,000	1,925,000	279,000	-118,000	1,014,000
Earnings Before Taxes	128.8%	2,450,000	-8,499,000	-1,239,000	-9,364,000	6,841,000	46,735,000	-19,265,000	-23,285,000	-36,054,000	-30,662,000	-40,549,000
EBT Margin	-25.0%	-0.06	-0.05	0.15	0.11	0.05	-0.18	-0.84	-1.56	-4.06	-	-
Net Income	282.2%	25,237,000	-13,855,000	14,972,000	-12,270,000	4,461,000	224,093,000	-19,981,000	-25,210,000	-36,333,000	-30,544,000	-41,563,000
Net Income Margin	293.7%	0.05	-0.03	0.82	0.83	0.83	0.82	-0.87	-1.59	-4.10	-	-
Free Cashflow	-74.8%	4,269,000	16,970,000	-3,777,000	-4,291,000	-11,544,000	62,031,000	-8,075,000	-37,097,000	-19,135,000	-28,560,000	-38,842,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	9.0%	526	483	484	443	460	460	211	231	233	253	279	311	349	384	271	226	255	282	308	346	322
Current Assets	7.9%	276	256	246	232	243	242	180	199	196	218	245	276	333	378	264	213	242	268	296	335	314
Cash Equivalents	-8.4%	108	118	113	81.00	123	176	94.00	63.00	122	190	168	120	114	86.00	124	107	47.00	69.00	83.00	83.00	72.00
Inventory	21.7%	31.00	26.00	24.00	23.00	22.00	15.00	20.00	13.00	4.00	6.00	6.00	2.00	-	-	-	-	-	-	-	-	-
Net PPE	-20.0%	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	4.00	4.00	5.00	5.00	6.00	6.00	6.00	6.00	6.00	6.00
Liabilities	12.2%	87.00	78.00	73.00	53.00	64.00	76.00	57.00	65.00	48.00	39.00	43.00	40.00	38.00	26.00	21.00	20.00	29.00	30.00	33.00	40.00	43.00
Current Liabilities	19.1%	64.00	53.00	47.00	37.00	47.00	56.00	44.00	50.00	45.00	34.00	39.00	35.00	32.00	25.00	21.00	19.00	28.00	28.00	30.00	37.00	43.00
Shareholder's Equity	8.3%	439	405	412	390	396	384	153	166	185	214	236	271	312	359	250	206	225	252	275	307	279
Retained Earnings	5.0%	-477	-503	-489	-504	-492	-496	-720	-700	-675	-639	-608	-566	-517	-463	-419	-382	-356	-324	-297	-260	-194
Additional Paid-In Capital	0.9%	917	908	901	894	888	881	874	867	860	853	844	838	829	822	670	588	581	576	572	567	473
Shares Outstanding	0.2%	70.00	70.00	70.00	70.00	69.00	69.00	69.00	69.00	69.00	68.00	68.00	68.00	62.00	60.00	57.00	55.00	54.00	54.00	54.00	52.00	30.00
Float	-	-	-	510	-	-	-	347	-	-	-	487	-	-	-	713	-	-	-	305	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-74.5%	4,325	16,986	-3,743	-4,267	-11,576	62,053	-7,824	-36,846	-18,884	-28,509	-38,783	-40,122	-41,191	-34,321	-29,224	-31,796	-24,170	-29,267	-41,676	-63,256	-27,638
Share Based Compensation	14.5%	7,773	6,788	6,473	6,115	6,372	6,041	6,676	6,031	6,131	6,199	5,717	7,126	6,257	5,558	4,851	4,209	4,965	3,758	3,464	2,893	2,582
Cashflow From Investing	-21.3%	-14,894	-12,277	35,534	-37,920	-42,660	19,040	38,265	-22,723	-50,041	47,849	85,993	44,834	68,643	-149,660	-31,217	88,790	1,916	15,213	41,363	-9,278	29,660
Cashflow From Financing	25.9%	695	552	158	90.00	1,190	361	542	423	1,212	2,680	887	1,106	712	146,399	77,561	2,414	373	53.00	494	83,187	291

KNSA Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Product revenue, net	$ 270,259	$ 220,180	$ 38,544
Costs and operating expenses:
Research and development	76,097	65,490	99,297
Selling, general and administrative	129,427	97,951	85,948
Total operating expenses	295,455	210,407	195,180
Income (loss) from operations	(25,196)	9,773	(156,636)
Other income	8,544	1,253	97
Income (loss) before income taxes	(16,652)	11,026	(156,539)
Benefit (provision) for income taxes	30,736	172,337	(1,385)
Net income (loss)	$ 14,084	$ 183,363	$ (157,924)
Net income (loss) per share attributable to common shareholders, basic	$ 0.20	$ 2.64	$ (2.30)
Net income (loss) per share attributable to common shareholders, diluted	$ 0.20	$ 2.60	$ (2.30)
Weighted average common shares outstanding, basic	70,058,952	69,382,275	68,576,810
Weighted average common shares outstanding, diluted	71,922,915	70,421,322	68,576,810
Comprehensive income (loss):
Net income (loss)	$ 14,084	$ 183,363	$ (157,924)
Other comprehensive income (loss):
Unrealized gain (loss) on short-term investments and currency translation adjustments, net of tax	(38)	110	(32)
Total other comprehensive income (loss)	(38)	110	(32)
Total comprehensive income (loss)	14,046	183,473	(157,956)
Product revenue, net
Revenue:
Product revenue, net	233,176	122,524	38,544
Costs and operating expenses:
Cost of goods sold	33,407	22,895	9,100
License and collaboration revenue
Revenue:
Product revenue, net	37,083	97,656
Costs and operating expenses:
Cost of goods sold	$ 56,524	$ 24,071	$ 835

KNSA Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 107,954	$ 122,715
Short-term investments	98,417	67,893
Accounts receivable, net	21,266	12,660
Contract asset		7,656
Inventory	31,122	21,599
Prepaid expenses and other current assets	17,538	10,537
Total current assets	276,297	243,060
Property and equipment, net	734	1,658
Operating lease right-of-use assets	11,931	5,385
Other long-term assets	827	5,824
Intangible asset, net	17,250	18,250
Deferred tax assets	219,283	185,495
Total assets	526,322	459,672
Current liabilities:
Accounts payable	8,246	7,899
Accrued expenses	44,667	30,112
Deferred revenue	307
Operating lease liabilities	2,253	3,301
Other current liabilities	8,193	5,754
Total current liabilities	63,666	47,066
Non-current liabilities:
Non-current deferred revenue	11,954	12,000
Non-current operating lease liabilities	10,005	2,618
Other long-term liabilities	1,858	1,839
Total liabilities	87,483	63,523
Commitments and contingencies (Note 16)
Shareholders' equity:
Additional paid-in capital	916,763	888,120
Accumulated other comprehensive income	6	44
Accumulated deficit	(477,950)	(492,034)
Total shareholders' equity	438,839	396,149
Total liabilities and shareholders' equity	526,322	459,672
Class A common shares
Shareholders' equity:
Common stock value	10	9
Class B common shares
Shareholders' equity:
Common stock value	1	1
Class A1 common shares
Shareholders' equity:
Common stock value	5	5
Class B1 common shares
Shareholders' equity:
Common stock value	$ 4	$ 4

About Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that completed Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

CEO	Mr. Sanj K. Patel
WEBSITE	kiniksa.com
INDUSTRY	Biotechnology
EMPLOYEES	220

Kiniksa Pharmaceuticals Ltd Frequently Asked Questions

What is the ticker symbol for Kiniksa Pharmaceuticals Ltd? What does KNSA stand for in stocks?

KNSA is the stock ticker symbol of Kiniksa Pharmaceuticals Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kiniksa Pharmaceuticals Ltd (KNSA)?

As of Fri Apr 19 2024, market cap of Kiniksa Pharmaceuticals Ltd is 1.18 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KNSA stock?

You can check KNSA's fair value in chart for subscribers.

What is the fair value of KNSA stock?

You can check KNSA's fair value in chart for subscribers. The fair value of Kiniksa Pharmaceuticals Ltd is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Kiniksa Pharmaceuticals Ltd is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KNSA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Kiniksa Pharmaceuticals Ltd a good stock to buy?

The fair value guage provides a quick view whether KNSA is over valued or under valued. Whether Kiniksa Pharmaceuticals Ltd is cheap or expensive depends on the assumptions which impact Kiniksa Pharmaceuticals Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KNSA.

What is Kiniksa Pharmaceuticals Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, KNSA's PE ratio (Price to Earnings) is 84.12 and Price to Sales (PS) ratio is 4.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KNSA PE ratio will change depending on the future growth rate expectations of investors.